search icon

    Market Snapshot

    • S&P Futures

      3,809.5

    • Dow Futures

      30,868

    • Nasdaq Futures

      11,633.25

    blog search icon

    Affimed N.V.

    (NASDAQ:AFMD)

    $2.77

    $-0.04

    -1.42%

    Affimed N.V. Chart

    AFMD Stock Price Today

    Affimed N.V. (AFMD) stock declined over -1.42% intraday to trade at $2.77 a share on NASDAQ. The stock opened with a loss of -0.36% at $2.75 and touched an intraday high of $2.795, falling -1.42% against the last close of $2.81. The stock went to a low of $2.695 during the session.

    Stock Snapshot

    $2.81

    Prev. Close

    423.59 Million

    Market Cap

    $2.695

    Day Low

    $2.75

    Open

    123.44 Million

    Number of Shares

    $2.795

    Day High

    -

    P/E ratio

    -0.66

    EPS (TTM)

    1.60

    Cash Flow per Share

    4.10

    Free Float in %

    1.12

    Book Value

    650,882

    Volume

    Affimed N.V. Historical Data

    DateOpenHighLowCloseVolume
    2022-06-30$2.75$2.795$2.695$2.77637,591
    2022-06-29$2.78$2.82$2.695$2.81600,800
    2022-06-28$2.96$2.96$2.75$2.781,208,200
    2022-06-27$2.71$2.975$2.71$2.921,253,900
    2022-06-24$2.77$2.865$2.71$2.715,447,600
    2022-06-23$2.76$2.85$2.7$2.841,099,100
    2022-06-22$2.5$2.8$2.46$2.731,098,000
    2022-06-21$2.55$2.655$2.54$2.561,027,600
    2022-06-17$2.34$2.595$2.34$2.481,232,200
    2022-06-16$2.32$2.35$2.23$2.32728,300

    Contact Details

    Technologiepark
    Im Neuenheimer Feld 582
    Heidelberg 69120
    Germany

    Webiste:AFMD

    49 6221 6743 60

    Company Information

    Employees-

    Beta2.42

    Sales or Revenue41.8 Million

    5Y Sales Change44.90%

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase I/IIa clinical trials for the treatment of advanced cancer patients; and AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma. The company has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; Roivant Sciences Ltd.; and Roche Holding AG, as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

    Frequently Asked Questions

    icon

    What is the current Affimed N.V. (AFMD) stock price?

    Affimed N.V. (NASDAQ: AFMD) stock price is $2.77 as of the last check on Thursday, June 30. During the trading session, AFMD stock reached the peak price of $2.795 while $2.695 was the lowest point it dropped to.

    icon

    AFMD's industry and sector of operation?

    The NASDAQ listed AFMD is part of Biotechnology industry that operates in the broader Health Care sector. Affimed N. V.

    icon

    Who are the executives of AFMD?

    Ms. Denise Mueller
    Chief Bus. Officer & Pres of Affimed Inc. and Member of Management Board
    Dr. Adi Hoess
    CEO, MD & Member of Management Board
    Mr. Angus W. Smith
    CFO & Member of Management Board
    Dr. Wolfgang Fischer
    MD, COO & Member of Management Board

    icon

    What is the AFMD stock price today?

    AFMD stock traded closed the last session at $2.77, which is $-0.04 or -1.42% lower than its previous close of $2.81. AFMD's current trading price is 24.22% lower than its 52-week high of $8.64 where as its distance from 52-week low of 2.23% is -67.94%.

    icon

    How many employees does AFMD have?

    Number of AFMD employees currently stands at -. AFMD operates from Technologiepark, Im Neuenheimer Feld 582, Heidelberg 69120, Germany.

    icon

    Link for AFMD official website?

    Official Webiste of $AFMD is: https://www.affimed.com

    icon

    How do I contact AFMD?

    AFMD could be contacted at AFMD operates from Technologiepark, Im Neuenheimer Feld 582, Heidelberg 69120, Germany, or at phone #49 6221 6743 60 and can also be accessed through its website.

    icon

    How many shares of AFMD are traded daily?

    AFMD stock volume for the day was 650,882 shares while in the previous session number of AFMD shares traded was 637,591 . The average number of AFMD shares traded daily for last 3 months was 2.02 Million.

    icon

    How much did AFMD change today?

    The percentage change in AFMD stock occurred in the recent session was -1.42% while the dollar amount for the price change in AFMD stock was $-0.04.

    icon

    What price range AFMD stock been trading in?

    In the recent session, the day high for AFMD stock was $2.795 while the low for AFMD stock touched on the day was $2.695.

    icon

    What is the market cap of AFMD currently?

    The market value of AFMD currently stands at 423.59 Million with its latest stock price at $2.77 and 123.44 Million of its shares outstanding.